Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis

Immunology

Volumn 142, Issue 2, 2014, Pages 216-226

  Li, Pengfei ^a   Bledsoe, Grant ^b   Yang, Zhi Rong ^a   Fan, Hongkuan ^a   Chao, Lee ^a   Chao, Julie ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CHARLESTON SOUTHERN UNIVERSITY   (United States)

Author keywords

High mobility group box 1; Kallistatin; Organ injury; Sepsis; Survival

Indexed keywords

ANTIINFLAMMATORY AGENT; CASPASE 3; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEPARIN; HIGH MOBILITY GROUP B1 PROTEIN; HUMAN RECOMBINANT KALLISTATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; NITRIC OXIDE; PLASMA PROTEIN; PROTECTIVE AGENT; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COUNT; BACTERIAL LOAD; BINDING SITE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NONHUMAN; ORGAN INJURY; POLYMICROBIAL SEPSIS; PRIORITY JOURNAL; SEPSIS; SPLEEN; SURVIVAL; UMBILICAL VEIN ENDOTHELIAL CELL; UREA NITROGEN BLOOD LEVEL;

HIGH MOBILITY GROUP BOX-1; KALLISTATIN; ORGAN INJURY; SEPSIS; SURVIVAL;

ANIMALS; APOPTOSIS; BLOOD UREA NITROGEN; CASPASE 3; CREATINE; DISEASE MODELS, ANIMAL; HMGB1 PROTEIN; HUMANS; INFLAMMATION; INJECTIONS, INTRAVENOUS; INTERLEUKIN-6; KIDNEY; LUNG; MALE; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; SEPSIS; SERPINS; SPLEEN; SURVIVAL RATE; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899094520     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12242     Document Type: Article

References (42)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10.
2. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003; 9:517-24.
3. Chao J, Chai KX, Chen LM et al. Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 1990; 265:16394-401.
4. Chao J, Tillman DM, Wang MY, Margolius HS, Chao L. Identification of a new tissue-kallikrein-binding protein. Biochem J 1986; 239:325-31.
5. Zhou GX, Chao L, Chao J. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem 1992; 267:25873-80.
6. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002; 100:3245-52.
7. Miao RQ, Chen V, Chao L, Chao J. Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol 2003; 284:C1604-13.
8. Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L, Chao J. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 2005; 52:1319-24.
9. Shen B, Gao L, Hsu YT, Bledsoe G, Hagiwara M, Chao L, Chao J. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol 2010; 299:H1419-27.
10. Shen B, Hagiwara M, Yao YY, Chao L, Chao J. Salutary effect of kallistatin in salt- induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 2008; 51:1358-65.
11. Gao L, Yin HS, Smith RJ, Chao L, Chao J. Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest 2008; 88:1157-66.
12. Yin H, Gao L, Shen B, Chao L, Chao J. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-α-induced nuclear factor κB activation. Hypertension 2010; 56:260-7.
13. Chao J, Yin H, Yao YY, Shen B, Smith RS Jr, Chao L. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther 2006; 17:1201-13.
14. Liu Y, Bledsoe G, Hagiwara M, Shen B, Chao L, Chao J. Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol 2012; 303:F1230-8.
15. Chen LM, Chao L, Chao J. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci 1997; 60:1431-5.
16. Lu SL, Tsai CY, Luo YH et al. Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection. Antimicrob Agents Chemother 2013; 57:5366-72.
17. Chao J, Schmaier A, Chen LM, Yang Z, Chao L. Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med 1996; 127:612-20.
18. Stadnicki A, Mazurek U, Gonciarz M et al. Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease. Dig Dis Sci 2003; 48:615-23.
19. Lin WC, Lu SL, Lin CF, Chen CW, Chao L, Chao J, Lin YS. Plasma kallistatin levels in patients with severe community-acquired pneumonia. Crit Care 2013; 17:R27.
20. Chen VC, Chao L, Chao J. Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim Biophys Acta 2000; 1479:237-46.
21. Fan H, Bitto A, Zingarelli B, Luttrell LM, Borg K, Halushka PV, Cook JA. Beta-arrestin 2 negatively regulates sepsis-induced inflammation. Immunology 2010; 130:344-51.
22. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420:885-91.
23. Chen VC, Chao L, Chao J. A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein. J Biol Chem 2000; 275:40371-7.
24. Chen VC, Chao L, Pimenta DC, Bledsoe G, Juliano L, Chao J. Identification of a major heparin-binding site in kallistatin. J Biol Chem 2001; 276:1276-84.
25. Xu D, Young J, Song D, Esko JD. Heparan sulfate is essential for high mobility group protein 1 (HMGB1) signaling by the receptor for advanced glycation end products (RAGE). J Biol Chem 2011; 286:41736-44.
26. Park JS, Gamboni-Robertson F, He Q et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290:C917-24.
27. Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-51.
28. Wang G, Han D, Zhang Y, Xie X, Wu Y, Li S, Li M. A novel hypothesis: up-regulation of HO-1 by activation of PPARγ inhibits HMGB1-RAGE signaling pathway and ameliorates the development of ALI/ARDS. J Thorac Dis 2013; 5:706-10.
29. Mehta RL, Bouchard J, Soroko SB, Ikizler TA, Paganini EP, Chertow GM, Himmelfarb J. Sepsis as a cause and consequence of acute kidney injury: sepsis as a cause and consequence of acute kidney injury. Intensive Care Med 2011; 37:241-8.
30. Frank AJ, Sheu CC, Zhao Y et al. BCL2 genetic variants are associated with acute kidney injury in septic shock. Crit Care Med 2012; 40:2116-23.
31. Shen B, Smith RS Jr, Hsu YT, Chao L, Chao J. Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression. J Biol Chem 2009; 284:35471-8.
32. Iba T, Kidokoro A, Yagi Y. The role of the endothelium in changes in procoagulant activity in sepsis. J Am Coll Surg 1998; 187:321-9.
33. Hotchkiss RS, Swanson PE, Freeman BD et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27:1230-51.
34. Wesche-Soldato DE, Lomas-Neira JL, Perl M, Jones L, Chung CS, Ayala A. The role and regulation of apoptosis in sepsis. J Endotoxin Res 2005; 11:375-82.
35. Chopra M, Reuben JS, Sharma AC. Acute lung injury: apoptosis and signaling mechanisms. Exp Biol Med (Maywood) 2009; 234:361-71.
36. Chung CS, Song GY, Lomas J, Simms HH, Chaudry IH, Ayala A. Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity. J Leukoc Biol 2003; 74:344-51.
37. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, Korsmeyer SJ, Karl IE. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A 1999; 96:14541-6.
38. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-50.
39. Qin S, Wang H, Yuan R et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203:1637-42.
40. Huston JM, Wang H, Ochani M et al. Splenectomy protects against sepsis lethality and reduces serum HMGB1 levels. J Immunol 2008; 181:3535-9.
41. high inflammatory monocytes in murine sepsis survivors. J Intern Med 2013; 274:381-90.
42. Valdes-Ferrer SI, Rosas-Ballina M, Olofsson PS et al. High-mobility group box 1 mediates persistent splenocyte priming in sepsis survivors: evidence from a murine model. Shock 2013; 40:492-5.